Target intelligence / Profile preview

Influenza hemagglutinin stem (HA stem)

Target
HA stem
Molecular classification
Glycoprotein, Class I viral fusion protein, Viral surface protein
01

Overview

The influenza hemagglutinin stem is the highly conserved domain at the base of the trimeric hemagglutinin glycoprotein found on the surface of influenza viruses[1][4][6]. It anchors the protein to the viral membrane and plays a key role in mediating fusion of the viral envelope with the host cell membrane after virus entry via endocytosis[1][4][6]. Unlike the immunodominant head domain, the stem is less variable across influenza subtypes, making it an attractive target for broadly neutralizing antibodies and universal vaccine strategies[2][5][6]. Structural studies have shown the stem domain undergoes conformational changes critical for membrane fusion, a process targeted by novel therapeutics aiming to block infection at an early stage[1][2][4][6]. The development of drugs and vaccines focusing on the HA stem holds promise for influenza prevention and therapy due to its functional conservation and essential role in the viral life cycle[2][5][6].

Other names
Hemagglutinin stemHA stemHemagglutinin stalkHA stalk
02

Mechanism of action

Neutralization of viral entry by blocking membrane fusion step through binding the stem domain; Prevention of conformational change required for viral-host membrane fusion; Inhibition of viral infectivity by broadly neutralizing stem-directed antibodies.

03

Biological functions

Membrane fusion (enables viral and host cell membranes to merge)Viral entry (facilitates the introduction of viral genetic material into host cells)Antigenic site (target of neutralizing antibodies)
04

Disease associations

Infection (major pathogenic factor in influenza virus infection)Pandemic potential (central to emergence of new, immune-evading strains)Immune escape (drives antigenic drift and shift in flu epidemiology)Vaccine target (critical for universal influenza vaccine development)
05

Safety considerations

Antigenic variation: The high mutation rate of hemagglutinin, especially outside the conserved stem, poses a challenge for broad, long-lasting immunity.Escape mutations: Viral adaptation could reduce efficacy of stem-targeted therapeutics or vaccines.Off-target immune responses: Potential for non-neutralizing antibodies or immune enhancement is a theoretical concern for novel therapeutics.
06

Interacting drugs

Broadly neutralizing antibodies

2 more in the full profile.

07

Biomarkers

Levels of anti-HA stem antibodies for patient selection or immune monitoring in vaccine trialsHemagglutinin subtype identification (relevant for diagnostic and surveillance purposes)

Beyond the preview

Go deeper on Influenza hemagglutinin stem (HA stem).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza hemagglutinin stem (HA stem).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call